1) Adult Onset: Patients who have GHD, either alone or associated with
multiple hormone deficiencies (hypopituitarism), as a result of
pituitary disease, hypothalamic disease, surgery, radiation therapy, or
2) Childhood Onset: Patients who were growth hormone deficient during
childhood as a result of congenital, genetic, acquired, or idiopathic
In general, confirmation of the diagnosis of adult GHD in both groups usually requires an appropriate growth hormone stimulation test.
Important Safety Information
Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses or in patients with active proliferative or severe non- proliferative diabetic retinopathy. Norditropin should not be used in patients with known hypersensitivity to somatropin or any of its excipients.
Somatropin should not be used or should be discontinued with any evidence of active malignancy. Patients with preexisting malignancy should be monitored carefully for any progression or reoccurrence.
Somatropin should not be used to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure as increased mortality may occur.
Deaths have been reported in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment and are treated with somatropin. Unless patients with Prader-Willi syndrome also have a diagnosis of GHD, Norditropin is not indicated for the treatment of patients who have growth failure due to genetically confirmed Prader-Willi syndrome.
Blood glucose levels should be monitored periodically as treatment with
somatropin may decrease insulin sensitivity. Patients with preexisting
diabetes or glucose intolerance should be monitored closely during
somatropin therapy. Doses of insulin or oral
|SOURCE Novo Nordisk|
Copyright©2007 PR Newswire.
All rights reserved